Omega-3 Fish Oil As Effective As Drugs For Some Children With ADHD By Jane Chang via Natural Blaze
Attention deficit hyperactivity disorder (ADHD) is quite common. It affects about one in 20 children and is three or four times more common in boys than in girls. Children with ADHD, which is characterised by inattention, hyperactivity and impulsivity, are more likely to drop out of school. Fortunately, drugs to treat the condition work well for 60-80% of children who take them. But that leaves 20-40% of children who have a poor response to the drugs or who suffer from side effects.
Some studies have shown that omega-3 fish oil may help with ADHD symptoms. What’s more, they’re safe and well-tolerated. However, the results of these studies have been mixed – some children get better, others get worse. We wanted to know whether these results depended on whether or not the children had enough omega-3 in their body to begin with.
Omega-3 fatty acids, such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are important for our brain, body, immune system and heart. We can only get them from food, such as oily fish, spinach and nuts.
Now is your chance to support Gospel News Network.
We love helping others and believe that’s one of the reasons we are chosen as Ambassadors of the Kingdom, to serve God’s children. We look to the Greatest Commandment as our Powering force.
Previous studies have found that children with ADHD eat less omega-3-containing food and have less omega-3 in their bodies than children without ADHD, so they are also more likely to show symptoms indicating a lack of omega-3, such as eczema, brittle nails, and dry and scaly skin. But in previous studies, omega-3 fatty acids were given to children with ADHD without checking if they were deficient in omega-3 in the first place.
In our study, published in the journal Translational Psychiatry, we examined 92 children, aged six to 18, diagnosed with ADHD. Half were randomly assigned to a group taking omega-3, EPA. The other half (the control group) were given a placebo. The trial lasted 12 weeks.
We measured the children’s progress with a continuous performance test (CPT), an objective cognitive assessment of attention, vigilance and impulsivity at the beginning and at the end of the trial. We found that children who were deficient in omega-3, measured in the blood, became more attentive and vigilant at the end of the 12 weeks when taking EPA. The difference was statistically significant, that is, unlikely to be the result of chance.
